Please Wait
Applying Filters...
menu
    • menu
    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Rilzabrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 13,206Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi's Wayrilz FDA Approved as First BTK Inhibitor for Immune
    Sanofi's Wayrilz FDA Approved as First BTK Inhibitor for Immune

    29 Aug 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-08-29-21-50-18-3141825

    PRESS RELEASE
    29 Aug 2025
    Share Share
    Sanofi's Rilzabrutinib Granted EU Orphan Designation
    Sanofi's Rilzabrutinib Granted EU Orphan Designation

    14 Aug 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-08-14-05-00-00-3133146

    PRESS RELEASE
    14 Aug 2025
    Share Share
    Rilzabrutinib Grants Orphan Designation for Sickle Cell Disease
    Rilzabrutinib Grants Orphan Designation for Sickle Cell Disease

    03 Jun 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-03-05-00-00-3092429

    PRESS RELEASE
    03 Jun 2025
    Share Share
    Rilzabrutinib granted orphan drug designation in US for 2 diseases
    Rilzabrutinib granted orphan drug designation in US for 2 diseases

    04 Apr 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-03-05-00-00-3054815

    PRESS RELEASE
    04 Apr 2025
    Share Share
    Clirnet teams-up African Medical Associations to transform healthcare education
    Clirnet teams-up African Medical Associations to transform healthcare education

    29 Apr 2024

    // BUSINESSMICRO

    https://businessmicro.in/business/clirnet-teams-up-with-african-medical-associations-to-revolutionize-healthcare-education/

    BUSINESSMICRO
    29 Apr 2024
    Share Share
    Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint in ITP
    Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint in ITP

    23 Apr 2024

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2024/2024-04-23-05-00-00-2867327

    PRESS RELEASE
    23 Apr 2024
    Share Share